Can thrice-delayed data turn out positive?
TG Therapeutics has made a lot of pleas for patience. First, in 2018, the company told investors that data on its combination cancer treatment would be ready by the end of 2019. Late last year, management said it’d be available in the first quarter of this year. Yesterday, the timeline distended further, and now the market has to wait another three months.
As STAT’s Adam Feuerstein points out, that tends not to be a good omen. TG Therapeutics’ explanation for the delay is that patients in the trial haven’t experienced enough tumor progression events to derive final data. “The longer it takes for the events to occur should point to a greater-than-expected benefit for” the company’s two drugs, CEO Mike Weiss told analysts and investors.
More often, however, long-delayed clinical trials turn up disappointing results, either because the drug being studied isn’t as effective as hoped, or the control arm performs better than expected. Or, every now and again, both.
Read more.
As STAT’s Adam Feuerstein points out, that tends not to be a good omen. TG Therapeutics’ explanation for the delay is that patients in the trial haven’t experienced enough tumor progression events to derive final data. “The longer it takes for the events to occur should point to a greater-than-expected benefit for” the company’s two drugs, CEO Mike Weiss told analysts and investors.
More often, however, long-delayed clinical trials turn up disappointing results, either because the drug being studied isn’t as effective as hoped, or the control arm performs better than expected. Or, every now and again, both.
Read more.
.png)
No hay comentarios:
Publicar un comentario